Midazolam for premedication in children: nasal vs. rectal administration

Area of Science:

• Anesthesiology
• Pediatric Medicine
• Pharmacology

Background:

• Midazolam (MDZ) is commonly used for pediatric premedication.
• Both rectal and nasal routes are utilized for MDZ administration.
• Comparing acceptance and efficacy of these routes is crucial for optimal patient care.

Purpose of the Study:

• To compare the acceptance and efficacy of rectal versus nasal midazolam administration in pediatric patients undergoing elective surgery.
• To evaluate sedation quality, onset of action, and patient tolerance for each administration route.
• To assess age-related differences in tolerance and side effects for both routes.

Main Methods:

• A randomized study involving 95 pediatric patients (8 months to 12 years) categorized by ASA status.
• Patients were allocated to receive either rectal (0.3 mg/kg) or nasal (0.2 mg/kg) midazolam.
• Tolerance was assessed during administration, and sedation quality was recorded post-administration.

Main Results:

• Nasal midazolam provided sedation comparable to rectal administration but with a quicker onset.
• Nasal administration was reported as more painful than the rectal route.
• Older children experienced more swallowing with nasal MDZ and modesty concerns with rectal MDZ.

Conclusions:

• Nasal midazolam is a viable alternative for pediatric premedication due to its faster onset, though pain is a concern.
• Rectal midazolam is better tolerated in younger children, while nasal administration may be preferred for older pediatric patients.
• Poor tolerance of nasal administration suggests its use should be reserved for situations without alternatives, and rectal administration should be avoided in older children.